High-dose cyclophosphamide for severe systemic lupus erythematosus

Abstract

Cytotoxic therapy is a cornerstone for patients with severe systemic lupus erythematosus (SLE). High-dose cyclophosphamide, 200 mg/kg, can induce a complete remission without the need for stem cell rescue in patients with autoimmune illnesses. Here we report on our first four patients treated for severe SLE with this treatment approach. Patients received cyclophosphamide, 200 mg/kg, divided over 4 days. Starting day 10, patients received filgrastim, 5 mg/kg/day, until their absolute neutrophil count (ANC) rose to 10.0 £ 10 ⁹=l for two consecutive days. Disease activity as evaluated by scores from the Systemic Lupus Activity Measure-2, the SLE Disease Activity Index and the Responder Index for Lupus Erythematosus were completed before and after high-dose therapy. Before high-dosecyclophosphamide,SLE disease duration ranged from 8 to 21 (mean 12.5) years. Their average disease activity measuredby SLAM-2 and SLEDAI was 15.5 (range 11–19) and 23.25 (range 20–26), respectively. At a median of 22 (range 12–39) months of follow-up, mean disease activity measured by SLAM-2 and SLEDAI decreased to 6.25 and 7.75, respectively. All patients experienced febrile neutropenia. No long-term morbidities or mortalities were observed. High dose cyclophosphamide is a therapy capable of decreasing disease severity in poor prognosis SLE patients. Future study is warranted for both refractory patients as well as primary therapy for patients with moderate to severe disease presentations.

Keywords

cyclophosphamide high-dose therapy SLAM SLE SLEDAI

Get full access to this article

View all access options for this article.

References

Osborne E , Jordan J , Hoak FC , Pschiere F Nitrogen mustard therapy in cutaneous blastomatous disease . JAMA 1947; 135: 1123–1128 .

Austin HA III , Klippel JH , Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs . New Engl J Med 1986; 314: 614–619 .

Gourley MF , Austin HAr , Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial . Ann Intern Med 1996; 125: 549–557 .

Boumpas DT , Austin HAr , Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis . Lancet 1992; 340: 741–745 .

Boumpas DT , Wheby MS , Jaffe ES et al. Synovitis in angioimmunoblastic lymphadenopathy with dysproteinemia simulating rheumatoid arthritis . Arthrit Rheum 1990; 33: 578–582 .

Boumpas DT , Yamada H , Patronas NJ et al. Pulse cyclophosphamide for severe neuropsychiatric lupus . Q J Med 1991; 81: 975–984 .

Klippel JH Indications for, and use of, cytotoxic agents in SLE . Lupus 1998; 7: 644–648 .

Hay EM , Bacon PA , Gordon C et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus . Q J Med 1993; 86: 447–458 .

Strand V , Gladman D , Isenberg D et al. Outcome measures to be used in clinical trials in systemic lupus erythematosus . J Rheumatol 1999; 26: 490–497 .

10.

Petri M , Hellmann D , Hochberg M Validity and reliability of lupus activity measures in the routine clinic setting . Medicine 1992; 71: 84–95 .

11.

Brodsky RA , Petri M , Smith BD et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease . Ann Intern Med 1998; 129: 1031–1035 .

12.

Brodsky RA , Smith BD Bone marrow transplantation for autoimmune diseases . Curr Opin Oncol 1999; 11: 83–86 .

13.

Brodsky RA High-dose cyclophosphamide for aplastic anemia and autoimmunity . Curr Opin Oncol 2002; 14: 143–146 .

14.

Brannagan TH , Pradhan A , Heiman-Patterson T et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP . J Neurol (in press).

15.

Brannagan TH , Pradhan A , Heiman-Patterson T et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory chronic inflammatory demyelinating polyneuropathy (CIDP) and other immune-mediated neuropathies . In: The 53rd Annual Meeting of the American Academy of Neurology, 5–11 May 2001, Philadelphia, PA.

16.

Tew K , Colvin M , Chabner B . Cancer Chemotherapy and Biotherapy: Principles and Practice, 2nd edn. Lippincott-Raven: Philadelphia, PA , 1996.

17.

Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthrit Rheum 1982; 25: 1271–1277 .

18.

Merrell M , Shulman LE Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus . J Chron Dis 1955; 1: 12–32 .

19.

Gripenberg M , Helve T Outcome of systemic lupus erythematosus. A study of 66 patients over 7 years with special reference to the predictive value of anti-DNA antibody determinations . Scand J Rheumatol 1991; 20: 104–109 .

20.

Cervera R , Khamashta MA , Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus . Medicine 1999; 78: 167–175 .

21.

Tyndall A , Fassas A , Passweg J et al. Autologous haematopoietic stem cell transplants for autoimmune disease—feasibility and transplant-related mortality. Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation, the European League Against Rheumatism and the International Stem Cell Project for Autoimmune Disease . Bone Marrow Transplant 1999; 24: 729–734 .

22.

Brodsky RA , Sensenbrenner LL , Jones RJ Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation . Blood 1996; 87: 491–494 .

23.

Brodsky RA , Sensenbrenner LL , Smith BD et al. Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia . Ann Intern Med 2001; 135: 477–483 .

24.

Mok CC , Lau CS , Wong RW Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy . Arthrit Rheum Arthrit Care Res 1998; 41: 831–837 .

25.

Ruiz-Irastorza G , Lima F , Alves J et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies . Br J Rheumatol 1996; 35: 133–138 .